Watson Rebecca’s Antares Pharma, Inc. ATRS Stock Holding History

Watson Rebecca’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,000	Closed	-$47K	–	89
2019 Q4	$47K	Buy	+10,000	New	+$40.9K	0.03%	83

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Watson Rebecca's ATRS Position: Q1 2020 in Review

Watson Rebecca sold out of Antares Pharma, Inc. (ATRS) in Q1 2020, closing a stake of 10,000 shares — an estimated $47K sold.

Watson Rebecca first reported a position in ATRS in Q4 2019 and held it in 1 quarter. The position peaked at $47K in Q4 2019. 154 funds tracked by Wall St. Rank hold ATRS as of Q1 2020.

Watson Rebecca reported no remaining Antares Pharma, Inc. position as of Q1 2020 after selling out during the quarter.
Watson Rebecca sold 10,000 Antares Pharma, Inc. shares in Q1 2020, an estimated $47K.
Watson Rebecca first reported a position in Antares Pharma, Inc. in Q4 2019 and held it in 1 quarter.
Watson Rebecca's Antares Pharma, Inc. position peaked at $47K in Q4 2019.
154 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2020.

Based on Watson Rebecca's 13F filing for Q1 2020, filed 14 May 2020.